JPH0367678B2 - - Google Patents

Info

Publication number
JPH0367678B2
JPH0367678B2 JP57115320A JP11532082A JPH0367678B2 JP H0367678 B2 JPH0367678 B2 JP H0367678B2 JP 57115320 A JP57115320 A JP 57115320A JP 11532082 A JP11532082 A JP 11532082A JP H0367678 B2 JPH0367678 B2 JP H0367678B2
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding
binding affinity
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP57115320A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5859994A (ja
Inventor
Eru Riideingu Kurisutofuaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YUNIBAASHITEI OBU TEKISASU SHISUTEMU ZA
Original Assignee
YUNIBAASHITEI OBU TEKISASU SHISUTEMU ZA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23068220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0367678(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by YUNIBAASHITEI OBU TEKISASU SHISUTEMU ZA filed Critical YUNIBAASHITEI OBU TEKISASU SHISUTEMU ZA
Publication of JPS5859994A publication Critical patent/JPS5859994A/ja
Publication of JPH0367678B2 publication Critical patent/JPH0367678B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/819—Multifunctional antigen or antibody
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP57115320A 1981-07-01 1982-07-01 組換えモノクローナル抗体 Granted JPS5859994A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US279248 1981-07-01
US06/279,248 US4474893A (en) 1981-07-01 1981-07-01 Recombinant monoclonal antibodies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP3138042A Division JPH084496B2 (ja) 1981-07-01 1991-06-10 トリオーマ細胞およびその製造方法
JP3138041A Division JPH04228067A (ja) 1981-07-01 1991-06-10 クアドローマ細胞およびその製造方法

Publications (2)

Publication Number Publication Date
JPS5859994A JPS5859994A (ja) 1983-04-09
JPH0367678B2 true JPH0367678B2 (en:Method) 1991-10-23

Family

ID=23068220

Family Applications (3)

Application Number Title Priority Date Filing Date
JP57115320A Granted JPS5859994A (ja) 1981-07-01 1982-07-01 組換えモノクローナル抗体
JP3138042A Expired - Lifetime JPH084496B2 (ja) 1981-07-01 1991-06-10 トリオーマ細胞およびその製造方法
JP3138041A Granted JPH04228067A (ja) 1981-07-01 1991-06-10 クアドローマ細胞およびその製造方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP3138042A Expired - Lifetime JPH084496B2 (ja) 1981-07-01 1991-06-10 トリオーマ細胞およびその製造方法
JP3138041A Granted JPH04228067A (ja) 1981-07-01 1991-06-10 クアドローマ細胞およびその製造方法

Country Status (6)

Country Link
US (1) US4474893A (en:Method)
EP (1) EP0068763B2 (en:Method)
JP (3) JPS5859994A (en:Method)
AT (1) ATE26464T1 (en:Method)
CA (1) CA1190873A (en:Method)
DE (1) DE3276007D1 (en:Method)

Families Citing this family (664)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401764A (en) * 1980-02-07 1983-08-30 Technicon Instruments Corporation Immunoassays employing labeled reagent and a conjugate having two binding sites
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
ES8504461A1 (es) * 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
CA1209907A (en) * 1982-04-12 1986-08-19 Richard M. Bartholomew Method of affinity purification employing monoclonal antibodies
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8318575D0 (en) * 1983-07-08 1983-08-10 Cobbold S P Antibody preparations
CA1231067A (en) * 1983-08-16 1988-01-05 Bioclones (Proprietary) Limited Monoclonal antibody to peroxidase and hybridoma producing it
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
US4777245A (en) * 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
US4634666A (en) * 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
EP0179872B1 (en) * 1984-04-23 1991-06-19 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4649106A (en) * 1984-06-01 1987-03-10 Dana-Farber Cancer Institute, Inc. Distinguishing subsets of human cells
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4818679A (en) * 1985-02-19 1989-04-04 The Trustees Of Columbia University In The City Of New York Method for recovering mutant cells
CH670098B (en:Method) * 1985-05-23 1989-05-12
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
WO1987005930A1 (en) * 1986-04-01 1987-10-08 Genelabs Incorporated Immortalized virus-specific tissue cells
WO1987005929A1 (en) * 1986-04-01 1987-10-08 Genelabs Incorporated Immortalized cells which produce tissue-specific products
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
JP2635343B2 (ja) * 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法
JPS62244392A (ja) * 1986-04-15 1987-10-24 Snow Brand Milk Prod Co Ltd ハイブリド−マを用いて抗体を産生する方法
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
US5853988A (en) * 1986-08-11 1998-12-29 Massachusetts Eye And Ear Infirmary Diagnosis of retinoblastoma
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US4874693A (en) * 1986-10-10 1989-10-17 Mark Bogart Method for assessing placental dysfunction
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE120761T1 (de) * 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
EP0371056A4 (en) * 1987-08-07 1990-12-19 Xoma Corporation Methods and compositions for mimicking antigenic determinants
US5086002A (en) * 1987-09-07 1992-02-04 Agen Biomedical, Ltd. Erythrocyte agglutination assay
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
FR2622444B1 (fr) * 1987-10-30 1990-08-03 Pasteur Institut Application de dinitro-trinitrophenyle et de ses derives ou d'anticorps anti-nitrophenyles a la modification de l'interaction entre des cellules sensibles d'un hote et un agent pathogene
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
EP0329184A3 (en) * 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
EP0338497A3 (en) * 1988-04-22 1990-05-16 Takeda Chemical Industries, Ltd. Bispecific hybrid monoclonal antibody
GB8813527D0 (en) * 1988-06-08 1988-07-13 Glennie M J Bispecific antibodies
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
FR2637600B1 (fr) 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
WO1990006772A1 (en) * 1988-12-22 1990-06-28 Oncogen Limited Partnership Novel monoclonal antibody to human carcinomas
US5242824A (en) * 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5639624A (en) * 1989-03-14 1997-06-17 Board Of Regents Of The University Of Nebraska Monoclonal antibodies specific for metallic cations and method therefor
CA2047717C (en) * 1989-03-14 2000-08-01 Fred W. Wagner Monoclonal antibodies for small moieties, methods therefor
US5972656A (en) * 1989-03-14 1999-10-26 Bionebraska, Inc. Mercury binding polypeptides and nucleotides coding therefore
DE3909708A1 (de) * 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
US5316932A (en) * 1989-03-24 1994-05-31 Duke University Homogeneous denatured human 06-guanine alkyltransferase prepared by immunoaffinity chromatography using monoclonal antibody specific for enzyme
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US5252711A (en) * 1989-06-01 1993-10-12 The Gillette Company Monoclonal antibodies useful in deodorizing skin and antibody fragments thereof
IL94872A (en) * 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same
US5980896A (en) * 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
US6932968B1 (en) 1989-07-26 2005-08-23 Dade Behring Marburg Gmbh Erythropoietin (EPO) peptides and antibodies directed against these
US5112951A (en) * 1989-07-28 1992-05-12 Hybritech Incorporated Separation of anti-metal chelate antibodies
ATE189682T1 (de) * 1989-08-16 2000-02-15 Chiron Corp Prohormonspaltungsplatzblockierungsantikörper
US5264341A (en) * 1989-08-30 1993-11-23 Eli Lilly And Company Selective cloning for high monoclonal antibody secreting hybridomas
US5583003A (en) * 1989-09-25 1996-12-10 Agen Limited Agglutination assay
GB8921880D0 (en) * 1989-09-28 1989-11-15 Medical Res Council Improvements in or relating to hybridomas
EP0515571B1 (en) * 1990-02-16 1998-12-02 Boston Biomedical Research Institute Hybrid reagents capable of selectively releasing molecules into cells
TW212184B (en:Method) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US7041293B1 (en) * 1990-04-03 2006-05-09 Genentech, Inc. HIV env antibodies
EP0460607A3 (en) * 1990-06-05 1992-04-01 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6248332B1 (en) 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
WO1992008802A1 (en) * 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
EP0575554A1 (en) * 1991-03-14 1993-12-29 Genentech, Inc. Novel beta integrin subunit
AU1929292A (en) * 1991-05-14 1992-12-30 Hybritech Incorporated Polymeric compositions having bound antibodies
SE469451B (sv) * 1991-06-28 1993-07-05 Anders Larsson Karakterisering eller bestaemning av maengden mammalieceller medelst antikroppar
JP2555804B2 (ja) * 1991-07-11 1996-11-20 日東紡績株式会社 前立腺由来酸性ホスファターゼに対するモノクローナル抗体、それを用いた測定法及び測定用キット
CA2122717C (en) * 1991-11-08 2003-07-15 David C. Anderson Hemoglobins as drug delivery agents
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
JPH05244987A (ja) * 1992-02-28 1993-09-24 Unitika Ltd 抗硫酸化チロシン抗体，その製造方法及び抗硫酸化チロシンモノクローナル抗体を産生するハイブリドーマ
US5518887A (en) * 1992-03-30 1996-05-21 Abbott Laboratories Immunoassays empolying generic anti-hapten antibodies and materials for use therein
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
JPH07506727A (ja) * 1992-05-22 1995-07-27 アジェン・リミテッド 凝集アッセイ用試薬
US6329507B1 (en) * 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
US5882875A (en) * 1992-10-27 1999-03-16 Queen's University At Kingston Methods for identifying multidrug resistant tumor cells
US6063621A (en) * 1992-10-27 2000-05-16 Queen's University At Kingston Antibodies to a multidrug resistance protein
WO1994013806A1 (en) * 1992-12-11 1994-06-23 The Dow Chemical Company Multivalent single chain antibodies
JP2553445B2 (ja) * 1992-12-17 1996-11-13 同仁医薬化工株式会社 抗体の安定化方法
WO1994014475A1 (en) * 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0608117A3 (en) * 1993-01-20 1996-01-17 Ono Pharmaceutical Co Antibodies for mevalonic acid and methods for determination of mevalonic acid.
US5705614A (en) * 1993-04-09 1998-01-06 Chiron Corporation Methods of producing antigen forks
US5466784A (en) * 1993-06-23 1995-11-14 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to salinomycin and method for detecting the same
EP0650735A3 (en) * 1993-07-09 1999-04-14 Akzo Nobel N.V. Kit and method for pretargeting
US5491071A (en) * 1993-08-03 1996-02-13 Abbott Laboratories Reagents and methods for the detection and quantification of testosterone in fluid samples
WO1995008637A1 (en) * 1993-09-21 1995-03-30 Washington State University Research Foundation Immunoassay comprising ligand-conjugated, ion channel receptor immobilized in lipid film
US5476939A (en) * 1993-12-30 1995-12-19 Abbott Laboratories Certain pyridyl and isoquinolyl carbinolamine derivatives
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US7258983B2 (en) 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
US5545527A (en) * 1994-07-08 1996-08-13 Visible Genetics Inc. Method for testing for mutations in DNA from a patient sample
US5728821A (en) * 1994-08-04 1998-03-17 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
US5792456A (en) * 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
US5972703A (en) * 1994-08-12 1999-10-26 The Regents Of The University Of Michigan Bone precursor cells: compositions and methods
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
DE69535690T2 (de) * 1994-12-02 2009-01-15 Schering Corp. Kostimulatorisches T-Zell-Oberflächen-Antigen SLAM
US20030086922A1 (en) * 1994-12-02 2003-05-08 David B. Ring Method of promoting an immune response with a bispecific antibody
AU717779C (en) * 1994-12-28 2002-12-05 University Of Kentucky Recombinant anti-idiotype antibody 3H1 sequences relating to human carcinoembryonic antigen
US20020187131A1 (en) * 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
JPH08311100A (ja) * 1995-03-13 1996-11-26 Terumo Corp ヒト肺腺癌に関するモノクローナル抗体および抗原、及びそれを用いた免疫測定方法
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US5837263A (en) * 1995-05-19 1998-11-17 The Regents Of The University Of California Leptospira membrane proteins
US6111079A (en) * 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
US5686071A (en) * 1995-06-06 1997-11-11 Per Immune Holdings, Inc. Polymer affinity system for the delivery of cytotoxic material and other compounds to sites of disease
US6117985A (en) 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
US6306575B1 (en) * 1995-06-16 2001-10-23 Stemcell Technologies, Inc. Methods for preparing enriched human hematopoietic cell preparations
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6350571B1 (en) 1996-02-01 2002-02-26 Vinata B. Lokeshwar Methods for detection and evaluation of bladder cancer
DE19605105A1 (de) * 1996-02-12 1997-08-14 Gsf Forschungszentrum Umwelt Neue Sonde zur Früherkennung von epithelialen Dysplasien des mehrschichtigen Plattenepithels sowie zur Tumordiagnostik und Tumortherapie von Plattenepithelkarzinomen
WO1997034632A1 (en) * 1996-03-20 1997-09-25 Immunomedics, Inc. Glycosylated humanized b-cell specific antibodies
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) * 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US7011812B1 (en) * 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
CA2266339A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
US6261791B1 (en) * 1997-03-10 2001-07-17 The Regents Of The University Of California Method for diagnosing cancer using specific PSCA antibodies
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
AU740904B2 (en) * 1997-03-20 2001-11-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
US7033774B2 (en) * 1997-04-21 2006-04-25 Glycozyme, Inc. Determination of recombinant glycosylated proteins and peptides in biological fluids
US6309874B1 (en) 1997-06-04 2001-10-30 Karolinska Innovations Ab Selection marker
SE9702120D0 (sv) * 1997-06-04 1997-06-04 Karolinska Innovations Ab New selection marker
US20020098190A1 (en) * 1997-06-13 2002-07-25 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
DE69940497D1 (de) 1998-01-15 2009-04-16 Ct Molecular Med & Immunology Bispezifische "targeting moiety" umfassend einen antikörper gegen cea (carcinoembryonic antigen) und die liganden-bindende region der il13rezeptor alpha untereinheit
EP1093457B8 (en) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU4441799A (en) * 1998-06-15 2000-01-05 Research Foundation Of The State University Of New York, The Monoclonal antibodies that recognize antigens associated with tumor metastasis
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6140083A (en) * 1998-07-23 2000-10-31 The Regents Of The University Of California Leptospiral outer membrane protein, LipL46
GB9819411D0 (en) * 1998-09-04 1998-10-28 Ks Biomedix Ltd Antibodies
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
JP4093757B2 (ja) 1999-08-24 2008-06-04 メダレックス， インコーポレイテッド ヒトｃｔｌａ−４抗体およびその使用
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
AU2001238342A1 (en) * 2000-02-17 2001-08-27 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
DK2236152T3 (da) 2000-04-12 2014-07-07 Novozymes Biopharma Dk As Albuminfusionsproteiner
US7094882B2 (en) * 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
WO2001080883A1 (en) * 2000-04-26 2001-11-01 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
NZ534864A (en) * 2000-05-08 2006-04-28 Celldex Therapeutics Inc Human monoclonal antibodies to dentritic cells
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
EP1294769B1 (en) 2000-06-16 2011-01-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
WO2001097855A2 (en) * 2000-06-20 2001-12-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
EP1345625B1 (en) 2000-11-28 2013-07-17 MedImmune, LLC Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US20020187100A1 (en) * 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
JP2005503116A (ja) 2001-02-09 2005-02-03 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
DE60213771T2 (de) * 2001-03-30 2007-08-16 The University of Massachusetts, Worcester Morpholinobildgebung und therapie
MXPA03008959A (es) 2001-04-02 2004-10-15 Wyeth Corp Pd-1, un receptor para b7-4 y sus usos.
MXPA03009408A (es) 2001-04-13 2004-01-29 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
AU2001286171B2 (en) * 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
US20070015144A9 (en) * 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
EA021242B9 (ru) 2001-06-26 2015-11-30 Эмджен Фримонт Инк. Антитела к остеопротегерин лиганду (опгл)
US6886964B2 (en) * 2001-06-26 2005-05-03 Allan Gardiner Illuminator with filter array and bandwidth controller
AU2003904154A0 (en) * 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
CA2454073C (en) * 2001-07-18 2012-08-28 Bionomics Limited Mutations in ion channels
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US20030035802A1 (en) * 2001-08-14 2003-02-20 Dewan Zeng Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7052860B2 (en) 2001-11-28 2006-05-30 University Of Florida Research Foundation Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
JP4376629B2 (ja) * 2002-01-08 2009-12-02 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌性胸部細胞において差次的に発現された遺伝子産物およびその使用方法
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20060046249A1 (en) * 2002-01-18 2006-03-02 Fei Huang Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways
AU2003217930A1 (en) * 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
JP4761710B2 (ja) * 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
EP1499352A4 (en) 2002-04-12 2006-10-11 Medimmune Inc ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
JP4643255B2 (ja) * 2002-06-10 2011-03-02 バクシネックス インコーポレーティッド 乳癌および膀胱癌において差次的に発現される遺伝子ならびにコードされるポリペプチド
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
NZ563328A (en) 2002-10-16 2009-08-28 Euro Celtique Sa Antibodies that bind cell-associated CA 125/0772P and methods of use thereof
DK1558648T3 (da) 2002-10-17 2012-04-23 Genmab As Humane monoklonale antistoffer mod cd20
MXPA05007019A (es) * 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004206250B8 (en) * 2003-01-21 2009-09-17 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US9243064B2 (en) * 2003-01-31 2016-01-26 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
AU2003901425A0 (en) * 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
US20050031625A1 (en) * 2003-03-28 2005-02-10 Elusys Therapeutics, Inc. Methods and compositions for conversion of antibody activity
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004256021A1 (en) * 2003-05-09 2005-01-20 University Of Massachusetts Non-human animals expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
WO2005009217A2 (en) * 2003-07-21 2005-02-03 Medimmune, Inc. Diagnosis of pre-cancerous conditions using pcdgf agents
ES2383328T3 (es) 2003-07-25 2012-06-20 Amgen, Inc Métodos relacionados con LDCAM y CRTAM
DK1660524T3 (da) 2003-08-15 2011-05-09 Univ Florida Identifikation af porphyromonas gingivalis virulens polynukleotider til diagnose, behandling, og monitorering af periodontale sygdomme
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005035754A1 (ja) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
CN1913921B (zh) * 2003-12-04 2012-02-22 瓦西尼斯公司 通过靶定暴露在细胞凋亡肿瘤细胞上的内部抗原杀死肿瘤细胞的方法
US7371381B2 (en) * 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
EP2332575B1 (en) 2003-12-23 2014-11-12 Genentech, Inc. Treatment of cancer with novel anti-IL 13 monoclonal antibodies
JP5010923B2 (ja) 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
US7311906B2 (en) * 2004-04-30 2007-12-25 Brigham Young University Anti-viral activity of an anti-thymidine kinase monoclonal antibody
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
US7837998B2 (en) * 2004-05-21 2010-11-23 Nathaniel Lallatin Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
US20100266495A1 (en) * 2004-05-21 2010-10-21 Brigham Young University Anti-Cancer Activity of an Anti-Thymidine Kinase Monoclonal Antibody
US8551486B2 (en) * 2004-05-21 2013-10-08 Savoy Pharmaceuticals, Inc. Monoclonal antibodies to human thymidine kinase to treat cancer
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
JP5060293B2 (ja) 2004-08-03 2012-10-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経機能におけるｔａｊ
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7306785B2 (en) * 2004-09-23 2007-12-11 General Electric Company Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
JP2008518947A (ja) * 2004-10-29 2008-06-05 エルシス セラピューティクス， インク． 免疫応答のクリアランス及び誘導におけるｃｒ１結合分子の使用
US20060127311A1 (en) * 2004-11-17 2006-06-15 Duke University Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
US20060115862A1 (en) * 2004-11-17 2006-06-01 Duke University Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2006073921A2 (en) * 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
DK1853718T3 (en) 2005-02-15 2015-11-09 Univ Duke ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY
PL2567976T3 (pl) 2005-03-23 2018-01-31 Genmab As Przeciwciała przeciw-cd38 przeznaczone do leczenia szpiczaka mnogiego
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CA2604855C (en) 2005-04-04 2016-11-01 Idexx Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
SI1876236T1 (sl) * 2005-04-08 2014-11-28 Chugai Seiyaku Kabushiki Kaisha Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi
US20060228367A1 (en) * 2005-04-08 2006-10-12 Medimmune, Inc. Antibodies against mammalian metapneumovirus
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
EP1885755A4 (en) 2005-05-05 2009-07-29 Univ Duke CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
JP5065253B2 (ja) 2005-05-06 2012-10-31 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１モノクローナル抗体とその使用法
EP1904630A4 (en) * 2005-06-16 2009-10-21 Bionomics Ltd METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
WO2006138739A2 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
ES2439709T3 (es) 2005-06-21 2014-01-24 Xoma (Us) Llc Anticuerpos y fragmentos de los mismos que se unen a la IL-1beta
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof
WO2007008604A2 (en) * 2005-07-08 2007-01-18 Bristol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
US20080307549A1 (en) 2005-08-03 2008-12-11 Adelaide Research & Innovation Pty Ltd. Polysaccharide Synthases
EP1919503B1 (en) 2005-08-10 2014-09-24 MacroGenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
WO2007027906A2 (en) * 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2007027867A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20090130776A1 (en) * 2005-09-01 2009-05-21 Canon Kabushiki Kaisha Binding protein molecule
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
EA014900B1 (ru) 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
JP5554925B2 (ja) 2006-01-20 2014-07-23 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座及び変異体ｒｏｓキナーゼ
EP2540741A1 (en) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
WO2007117410A2 (en) * 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
DK2447359T3 (en) 2006-04-14 2016-02-08 Cell Signaling Technology Inc Genetic defects and mutated ALK kinase in human solid tumors
WO2007127335A2 (en) * 2006-04-27 2007-11-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
WO2007147090A2 (en) 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
US20080305111A1 (en) * 2006-06-22 2008-12-11 Vaccinex, Inc. Anti-C35 antibodies for treating cancer
PT2029173T (pt) 2006-06-26 2016-11-02 Macrogenics Inc Anticorpos específicos fc rib e seus métodos de uso
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
JP2009544630A (ja) * 2006-07-26 2009-12-17 デイアメデイカ・インコーポレイテツド 代謝障害の診断及び治療方法
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2008028192A2 (en) 2006-09-01 2008-03-06 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
EP2354254A1 (en) 2006-09-06 2011-08-10 Ortho-McNeil Pharmaceutical, Inc. Biomarkers for assessing response to C-met treatment
WO2008037257A2 (en) 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
EP2099823B2 (en) 2006-12-01 2022-02-09 Seagen Inc. Variant target binding agents and uses thereof
BRPI0719409A2 (pt) 2006-12-18 2014-02-11 Genentch Inc "regiões variáveis da cadeia pesada ("vh"), sequências da cadeia vh, ácido nucléico, vetor, célula, anticorpos, uso do anticorpo, método para produzir um anticorpo, anticorpo anti-notch3 e forma humanizada do anticorpo"
MX2009006709A (es) 2006-12-20 2009-07-02 Xoma Technology Ltd Tratamiento de enfermedades relacionadas con il-1beta.
DK2740744T3 (da) 2007-01-09 2018-04-23 Biogen Ma Inc Sp35-antistoffer og anvendelser deraf
KR20090108713A (ko) 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US20090068684A1 (en) * 2007-03-26 2009-03-12 Cell Signaling Technology, Inc. Serine and threoninephosphorylation sites
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
MX2009011996A (es) 2007-05-07 2010-04-21 Medimmune Llc Anticuerpos anti-coestimulador inducible y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunologica.
US20100291073A1 (en) 2007-05-14 2010-11-18 Medimmune, Llc Methods of reducing eosinophil levels
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
WO2009014708A2 (en) * 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US20090087860A1 (en) * 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
BRPI0817108B8 (pt) 2007-09-21 2021-05-25 Univ California composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.
EP4368721A3 (en) 2007-09-26 2024-12-18 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP3072963B1 (en) 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
MX2010004735A (es) 2007-10-31 2010-05-20 Idexx Lab Inc Diva (infeccion diferenciada de animales vacunados) de ehrlichia canis.
EP2570137A3 (en) * 2007-11-07 2013-08-21 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
US10365224B2 (en) 2007-12-06 2019-07-30 Genalyte, Inc. Label-free optical sensors
CN101945891A (zh) 2007-12-20 2011-01-12 爱克索马技术有限公司 治疗痛风的方法
CA2710680C (en) * 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
CN102037007A (zh) * 2008-01-25 2011-04-27 奥尔胡斯大学 选择性外部位点抑制papp-a对igfbp-4的活性
CA2713462C (en) 2008-01-29 2020-04-14 Fred Hutchinson Cancer Research Center Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP2260102A1 (en) 2008-03-25 2010-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
ES2458541T5 (en) 2008-05-02 2025-08-04 Seagen Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
WO2009155932A2 (en) 2008-06-25 2009-12-30 H. Lundbeck A/S Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
WO2009158040A2 (en) * 2008-06-26 2009-12-30 University Of South Florida Cancer platinum resistance detection and sensitization method
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
EP4071169A2 (en) 2008-08-25 2022-10-12 Dana Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
EP2347247B1 (en) 2008-10-27 2019-06-26 Genalyte, Inc. Biosensors based on optical probing and sensing
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
AR073997A1 (es) 2008-10-29 2010-12-15 Wyeth Corp Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
US8642280B2 (en) 2008-11-07 2014-02-04 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
WO2010069331A2 (en) 2008-12-19 2010-06-24 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
CA2748757A1 (en) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
PL2881402T3 (pl) 2009-02-12 2017-10-31 Cell Signaling Technology Inc Ekspresja zmutowanej ROS w ludzkim raku wątroby
EP2396035A4 (en) 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
US20110311521A1 (en) 2009-03-06 2011-12-22 Pico Caroni Novel therapy for anxiety
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
NO2427212T3 (en:Method) 2009-05-08 2018-01-20
JP2012528079A (ja) 2009-05-25 2012-11-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためのインテグリンリガンドの連続投与
AU2010278959A1 (en) 2009-07-31 2012-02-02 Amgen Inc. Polypeptides that bind tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods
BR112012003064B8 (pt) 2009-08-13 2021-05-25 Crucell Holland Bv anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
WO2011036118A1 (en) 2009-09-22 2011-03-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
EP2483289B2 (en) 2009-10-02 2025-03-26 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
EP2486141B1 (en) 2009-10-07 2018-01-10 MacroGenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
US9588121B2 (en) 2009-11-06 2017-03-07 Go Therapeutics, Inc. Method for early detection of cancer
CA2778953C (en) 2009-11-13 2020-01-14 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
WO2011082345A2 (en) * 2009-12-30 2011-07-07 Brigham Young University Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
RU2573994C2 (ru) 2010-02-10 2016-01-27 Иммьюноджен, Инк Антитела против cd20 и их применение
EP2542578A1 (en) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c and brain cancers
EP2544715A2 (en) 2010-03-09 2013-01-16 Board Of Regents, University Of Texas System Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
JP2013528360A (ja) 2010-04-09 2013-07-11 アムジェン インコーポレイテッド Ｂｔｎｌ９タンパク質、核酸および抗体ならびにそれらの使用
EP2561076A1 (en) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
CA2799536C (en) 2010-06-03 2020-03-10 Idexx Laboratories, Inc. Markers for renal disease
EP2580239A1 (en) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mammalian sterile 20-like kinase 3
US8735548B2 (en) 2010-06-30 2014-05-27 Amgen Inc. Antibodies which bind to SCNN1A/TNFRSF1A fusion proteins and methods of use thereof
AU2011274472B2 (en) 2010-07-09 2017-03-30 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
HRP20191305T1 (hr) 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
AU2011277983C1 (en) 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
EA201300145A1 (ru) 2010-07-16 2013-12-30 Мерк Патент Гмбх Пептид для применения в лечении рака молочной железы и/или метастазов в кости
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
CN103221426B (zh) 2010-08-16 2016-01-13 安姆根公司 结合肌肉生长抑制素的抗体、组合物和方法
MX353476B (es) 2010-09-02 2018-01-15 Vaccinex Inc Star Anticuerpos anti-cxcl13 y metodos para usarlos.
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
ES3004351T3 (en) 2010-10-22 2025-03-12 Seagen Inc Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
KR101973930B1 (ko) 2010-11-05 2019-04-29 자임워크스 인코포레이티드 Fc 도메인 내의 돌연변이를 갖는 안정한 이종이량체 항체 디자인
EP3266881B1 (en) 2010-11-05 2019-12-25 Genalyte, Inc. Optical analyte detection systems and methods of use
EP2640738A1 (en) 2010-11-15 2013-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
SI2644698T1 (en) 2010-11-17 2018-05-31 Chugai Seiyaku Kabushiki Kaisha MULTISPECIFIC ANTIGEN-TUBULAR MOLECULAR, WITH AN ALTERNATIVE FUNCTION TO THE FACTOR OF BLOOD VIOLATION VIII
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
CN106039306A (zh) 2011-03-30 2016-10-26 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
KR20140122649A (ko) 2011-04-21 2014-10-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (ADCs) 및 그의 용도
EP2707383B1 (en) 2011-05-13 2018-04-18 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
US9187567B2 (en) 2011-05-18 2015-11-17 Parkinson's Institute Assay to determine LRRK2 activity in parkinson's disease
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US9181553B2 (en) 2011-06-06 2015-11-10 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Method of treatment of breast cancers over-expressing the SHP2 signature genes
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
LT2717898T (lt) 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc. Pro-koagulianto junginiai ir jų gavimo būdai
AU2012275346B2 (en) 2011-06-29 2016-03-17 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
EP2742953B1 (en) 2011-08-11 2021-09-22 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
EP2760463B1 (en) 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
EP2776022A1 (en) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
CN104254342A (zh) 2011-12-14 2014-12-31 西雅图基因公司 新抗体药物缀合物(adc)及其用途
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
EP2800583A1 (en) 2012-01-02 2014-11-12 Novartis AG Cdcp1 and breast cancer
NZ626620A (en) 2012-01-10 2016-07-29 Biogen Ma Inc Enhancement of transport of therapeutic molecules across the blood brain barrier
CA2865677C (en) 2012-02-02 2021-08-10 Conicet Hahb11 provides improved plant yield and tolerance to abiotic stress
EP2812702B1 (en) 2012-02-10 2019-04-17 Seattle Genetics, Inc. Diagnosis and management of CD30-expressing cancers
JP6193275B2 (ja) 2012-03-02 2017-09-06 ヴァクシネックス， インコーポレイテッド Ｂ細胞媒介炎症性疾患を治療するための方法
WO2013134138A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
EP3907506A1 (en) 2012-03-12 2021-11-10 The Board of Trustees of the University of Illinois Optical analyte detection systems with magnetic enhancement and methods of their use
US20150266961A1 (en) 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
WO2013158859A1 (en) 2012-04-18 2013-10-24 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
WO2013170054A2 (en) 2012-05-09 2013-11-14 Advanced Animal Diagnostics, Inc. Autofocus method for imaging a biological sample and cartridge for use therein
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
BR112014028306A2 (pt) 2012-05-15 2018-04-17 Morphotek, Inc. métodos para tratamento de câncer gástrico.
IN2014KN02831A (en:Method) 2012-05-24 2015-05-08 Mountgate Group Ltd
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
EP2854841B1 (en) 2012-06-04 2017-02-22 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
EP2866831A1 (en) 2012-06-29 2015-05-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
WO2014006114A1 (en) 2012-07-05 2014-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
US20140024015A1 (en) 2012-07-18 2014-01-23 Idexx Laboratories, Inc. Boone Cardiovirus
WO2014015148A1 (en) 2012-07-19 2014-01-23 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
ES2771324T3 (es) 2012-08-03 2020-07-06 Dana Farber Cancer Inst Inc Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
CN109369808B (zh) 2012-08-24 2023-11-07 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
JP6352920B2 (ja) 2012-09-04 2018-07-04 セレクティス 多重鎖キメラ抗原受容体およびその使用
PL2900686T3 (pl) 2012-09-28 2021-01-25 The University Of North Carolina At Chapel Hill Wektory aav ukierunkowane na oligodendrocyty
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
EP3666285A3 (en) 2012-10-29 2020-06-24 The University of North Carolina at Chapel Hill Compositions and methods for inhibiting pathogen infection
WO2014122605A1 (en) 2013-02-08 2014-08-14 Friedrich Miescher Institute For Biomedical Research Novel methods for the targeted introduction of viruses into cells
US20160002325A1 (en) 2013-03-08 2016-01-07 Vaccinex, Inc. Anti-cxcl13 antibodies and associated epitope sequences
EP2778176A1 (en) 2013-03-12 2014-09-17 Sanofi Compositions and methods for analyzing histidine phosphorylation
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
WO2014143637A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The University Of Illinois Methods and compositions for enhancing immunoassays
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
EP2970483A2 (en) 2013-03-15 2016-01-20 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
EP2981822B1 (en) 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions and methods for growth factor modulation
AU2014266833B2 (en) 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
WO2014188423A1 (en) 2013-05-21 2014-11-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mast cell related pathologies
DK3309248T3 (da) 2013-05-29 2021-08-02 Cellectis Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system
WO2014197369A1 (en) 2013-06-06 2014-12-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
US20160175401A1 (en) 2013-07-31 2016-06-23 Dana-Farber Cancer Institute Inc. Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
RU2730594C2 (ru) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3063317B1 (en) 2013-10-28 2020-06-03 DOTS Technology Corp. Allergen detection
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
CN106029874B (zh) 2013-12-16 2020-09-15 北卡罗来纳-查佩尔山大学 浆细胞样树突状细胞的耗竭
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
KR102329024B1 (ko) 2013-12-23 2021-11-19 바이엘 파마 악티엔게젤샤프트 키네신 스핀들 단백질(ksp)과의 항체 약물 접합체 (adcs)
AU2015206603B9 (en) 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
BR112016017132B1 (pt) 2014-01-28 2024-01-30 Quest Diagnostics Investments Incorporated Métodos para identificar uma zona de célula tipo tronco de câncer, uma zona de transição de adenoma-adenocarcinoma, um tumor de cólon, células-tronco de câncer, um indivíduo com câncer colorretal provável de responder favoravelmente ao tratamento com uma terapia alvejada pela via nf-kb, um indivíduo com perda genômica de 18q/smad4 e de 10q/pten, para diagnosticar um indivíduo com alto grau de adenoma de cólon e adenocarcinoma inicial, e para determinar a probabilidade de um tumor de cólon em um indivíduo passar por uma transformação invasiva se deixado sem tratamento e a probabilidade de um indivíduo com câncer colorretal (crc) responder favoravelmente ao tratamento com uma terapia alvejada pela via tgf-beta, e, kit para identificar uma região de transição de (...).
WO2015130766A1 (en) 2014-02-25 2015-09-03 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
CN106103475B (zh) 2014-03-11 2021-01-12 塞勒克提斯公司 产生同种异体移植相容的t细胞的方法
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
KR102352573B1 (ko) 2014-04-04 2022-01-18 바이오노믹스 인코포레이티드 Ｌｇｒ５에 결합하는 인간화된 항체들
US11058768B2 (en) 2014-04-16 2021-07-13 Biocon Ltd. Stable protein formulations comprising a molar excess of sorbitol
JP6832709B2 (ja) 2014-05-16 2021-02-24 メディミューン，エルエルシー 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子
US20170137824A1 (en) 2014-06-13 2017-05-18 Indranil BANERJEE New treatment against influenza virus
US10308935B2 (en) 2014-06-23 2019-06-04 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
AU2015280436A1 (en) 2014-06-23 2017-02-02 Bionomics, Inc. Antibodies that bind LGR4
WO2016001830A1 (en) 2014-07-01 2016-01-07 Friedrich Miescher Institute For Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
EP3183002B1 (en) 2014-08-21 2021-03-03 Walter Reed Army Institute of Research Monoclonal antibodies for treatment of microbial infections
CA2959775A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
DK3218005T5 (da) 2014-11-12 2024-10-14 Seagen Inc Glycan-interagerende forbindelser og anvendelsesfremgangsmåder
AU2015349759B2 (en) 2014-11-21 2022-01-06 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
WO2016081835A2 (en) 2014-11-21 2016-05-26 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
ES3015000T3 (en) 2014-12-08 2025-04-28 Dana Farber Cancer Inst Inc Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
JP6743015B2 (ja) 2014-12-15 2020-08-19 バイエル ファーマ アクチエンゲゼルシャフト Ｋｓｐ阻害剤の脱グリコシル化抗ｔｗｅａｋｒ抗体との抗体薬物複合体（ａｄｃ類）
AU2016232749B2 (en) 2015-03-18 2021-09-23 The Johns Hopkins University Novel monoclonal antibody inhibitors targeting potassium channel KCNK9
RS61438B1 (sr) 2015-03-31 2021-03-31 Medimmune Ltd Novi oblik il33, mutirani oblici il33, antitela, testovi i postupci za njihovu upotrebu
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
EP3310440A1 (de) 2015-06-22 2018-04-25 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
WO2016207090A2 (en) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Site specific homogeneous with ksp inhibitors
WO2016207104A1 (de) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern
WO2016207094A1 (de) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
CA2986314C (en) 2015-06-30 2024-04-23 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
JP2018528191A (ja) 2015-08-19 2018-09-27 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー 抗体を生成する新規な方法
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017072669A1 (en) 2015-10-28 2017-05-04 Friedrich Miescher Institute For Biomedical Research Tenascin-w and biliary tract cancers
CN118725134A (zh) 2015-11-08 2024-10-01 豪夫迈·罗氏有限公司 筛选多特异性抗体的方法
SG11201803213XA (en) 2015-11-12 2018-05-30 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
KR102784832B1 (ko) 2015-12-28 2025-03-21 추가이 세이야쿠 가부시키가이샤 Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
WO2017151836A1 (en) 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
CN108697799A (zh) 2016-03-22 2018-10-23 生态学有限公司 抗lgr5单克隆抗体的施用
WO2017162663A1 (de) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
TW202402326A (zh) 2016-04-28 2024-01-16 日商中外製藥股份有限公司 含抗體製劑
US11001636B2 (en) 2016-06-15 2021-05-11 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
EP3492591A4 (en) 2016-07-26 2020-04-01 Shizuoka Prefecture ANTI-B7-H4 ANTIBODIES
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
SG11201901961SA (en) 2016-09-06 2019-04-29 Chugai Pharmaceutical Co Ltd Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
AU2017326751B2 (en) 2016-09-16 2024-10-10 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
US11052149B2 (en) 2016-09-19 2021-07-06 The University Of North Carolina At Chapel Hill Methods and compositions for inducing an immune response
KR20190064636A (ko) 2016-10-19 2019-06-10 메디뮨 엘엘씨 항-o1 항체 및 이의 용도
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
WO2018112033A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs
JP7174704B2 (ja) 2016-12-21 2022-11-17 バイエル・アクチエンゲゼルシヤフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
AU2017380871C1 (en) 2016-12-21 2025-05-15 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
AU2018226824A1 (en) 2017-03-03 2019-09-19 Seagen Inc. Glycan-interacting compounds and methods of use
JP2020510023A (ja) 2017-03-09 2020-04-02 ダイアメディカ， インコーポレイテッド 組織カリクレイン１の剤形
ES3004084T3 (en) 2017-04-22 2025-03-11 Immunomic Therapeutics Inc Improved lamp constructs
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN111010867B (zh) 2017-05-30 2023-05-12 俄克拉何马大学董事会 抗双皮层蛋白样激酶1抗体及其使用方法
CA3065328C (en) 2017-06-21 2023-08-15 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
WO2019028096A1 (en) 2017-08-02 2019-02-07 The Wistar Institute Of Anatomy And Biology METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
US20200172933A1 (en) 2017-08-18 2020-06-04 Friedrich Miescher Institute For Biomedical Research Novel methods for the targeted introduction of viruses into cells and tissues
EP4265257A1 (en) 2017-09-01 2023-10-25 East Carolina University Combination of a j-series prostaglandin-ethanolamide and a checkpoint inhibitor for use in treating cancer
CN111108202B (zh) 2017-09-29 2024-10-22 中外制药株式会社 具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂
US20200317783A1 (en) 2017-10-06 2020-10-08 Ono Pharmaceutical Co., Ltd. Bispecific antibody
IL316538A (en) 2017-10-11 2024-12-01 Seagen Inc Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
EP3705496A4 (en) 2017-11-01 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIBODY VARIANT AND ISOFORM WITH REDUCED BIOLOGICAL ACTIVITY
CA3080799A1 (en) 2017-11-01 2019-05-09 Seattle Genetics, Inc. Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
AU2018364630A1 (en) 2017-11-09 2020-05-21 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
SG11202006441SA (en) 2018-01-15 2020-08-28 Epiaxis Therapeutics Pty Ltd Agents and methods for predicting response to therapy
EP3746079A1 (en) 2018-01-31 2020-12-09 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
TWI890481B (zh) 2018-02-09 2025-07-11 日商小野藥品工業股份有限公司 雙特異性抗體
WO2019168897A2 (en) 2018-02-28 2019-09-06 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
ES2962762T3 (es) 2018-03-08 2024-03-21 Purepharm Inc Métodos y composiciones para la prevención y el tratamiento de afecciones relacionadas con la alfa-sinucleína
EP3768714A1 (en) 2018-03-23 2021-01-27 Seagen Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
AU2019257249A1 (en) 2018-04-06 2020-10-15 Dana-Farber Cancer Institute, Inc. KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
KR102861021B1 (ko) 2018-05-07 2025-09-17 젠맵 에이/에스 항-pd-1 항체 및 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
CA3096705A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CA3100004A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
AU2019287468B2 (en) 2018-06-12 2024-10-10 The University Of North Carolina At Chapel Hill Synthetic liver-tropic adeno-associated virus capsids and uses thereof
AU2019289506A1 (en) 2018-06-18 2021-02-04 Bayer Aktiengesellschaft Binder-drug conjugates directed against CXCR5, having enzymatically cleavable linkers and improved activity profile
AU2019297324B9 (en) 2018-07-03 2022-07-07 Gilead Sciences, Inc. Antibodies that target HIV gp120 and methods of use
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
JP2021535100A (ja) 2018-08-24 2021-12-16 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. Ｍ２マクロファージ極性化を調節する方法及び治療におけるその使用
CA3113059A1 (en) 2018-09-21 2020-03-26 The University Of North Carolina At Chapel Hill Synthetic binding agents for limiting permeation through mucus
SG11202103342QA (en) 2018-10-01 2021-04-29 Seagen Inc Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
RU2741095C2 (ru) * 2018-12-29 2021-01-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения клеточных линий, стабильно продуцирующих человеческие моноклональные антитела класса igg
WO2020163225A1 (en) 2019-02-05 2020-08-13 Seattle Genetics, Inc. Anti-cd228 antibodies and antibody-drug conjugates
CA3131268A1 (en) 2019-02-27 2020-09-03 Epiaxis Therapeutics Pty Ltd Methods and agents for assessing t-cell function and predicting response to therapy
BR112021017144A2 (pt) 2019-03-08 2021-11-09 Genentech Inc Ensaio para detectar uma proteína associada à membrana, métodos para quantificar a concentração de proteína circulante, para determinar se um paciente com linfoma de células b tem probabilidade de exibir uma resposta a uma terapia anti-cd20, para determinar a afinidade de um anticorpo anti-cd20, para determinar a ativação de células t e método de tratamento de um tumor
WO2020185763A1 (en) 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
EP3947442A2 (en) 2019-03-28 2022-02-09 Danisco US Inc. Engineered antibodies
TWI862565B (zh) 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
MX2021012171A (es) 2019-04-09 2021-12-10 Abcuro Inc Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1).
EP3962529A4 (en) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
EP3959293B1 (en) 2019-05-20 2024-11-13 NIRvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
WO2020236828A1 (en) 2019-05-20 2020-11-26 Nirvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
JP7684656B2 (ja) 2019-06-11 2025-05-28 小野薬品工業株式会社 免疫抑制剤
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
AU2020322765A1 (en) 2019-07-30 2022-02-24 Ono Pharmaceutical Co., Ltd. Bispecific antibody
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein
CN114867751B (zh) 2019-08-12 2024-11-29 阿帕特夫研究和发展有限公司 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
EP4034154A1 (en) 2019-09-25 2022-08-03 Seagen Inc. Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
EP4038101A2 (en) 2019-10-04 2022-08-10 Seagen Inc. Anti-pd-l1 antibodies and antibody-drug conjugates
CA3153850A1 (en) 2019-10-18 2021-04-22 Teri Heiland Improved lamp constructs comprising cancer antigens
CA3160151A1 (en) 2019-11-04 2021-05-14 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
US20230027495A1 (en) 2019-11-07 2023-01-26 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
EP4093513A4 (en) 2020-01-24 2024-05-08 Dana-Farber Cancer Institute, Inc. USE OF BIOMARKERS TO IMPROVE IMMUNOTHERAPY
IL295202A (en) 2020-01-31 2022-10-01 Seagen Inc Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
AU2021267856A1 (en) 2020-05-05 2022-12-01 The University Of North Carolina At Chapel Hill Modified adeno-associated virus 5 capsids and uses thereof
CN116390770A (zh) 2020-05-13 2023-07-04 思进股份有限公司 使用抗cd30抗体-药物缀合物的组合治疗癌症的方法
WO2021247908A1 (en) 2020-06-03 2021-12-09 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
US20230295330A1 (en) 2020-08-04 2023-09-21 Seagen Inc. Anti-cd228 antibodies and antibody-drug conjugates
CN116390750A (zh) 2020-09-04 2023-07-04 罗格斯新泽西州立大学 SARS-CoV-2疫苗和抗体
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
WO2022081436A1 (en) 2020-10-15 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
WO2022101358A1 (en) 2020-11-11 2022-05-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
IL302836A (en) 2020-11-17 2023-07-01 Seagen Inc Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
WO2022119976A1 (en) 2020-12-01 2022-06-09 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
WO2022147108A1 (en) 2020-12-30 2022-07-07 Immunomic Therapeutics, Inc. Anti-hvem antibodies
US20240115720A1 (en) 2021-01-13 2024-04-11 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
CA3204731A1 (en) 2021-01-13 2022-07-21 John T. POIRIER Anti-dll3 antibody-drug conjugate
US12365739B2 (en) 2021-03-24 2025-07-22 Wake Forest University Health Sciences Monoclonal antibodies to angiotensin-(1-12), compositions including the same, and methods of use thereof
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
IL307241A (en) 2021-03-26 2023-11-01 Abcuro Inc Antibodies against KLRG1
WO2022212836A1 (en) 2021-04-01 2022-10-06 Pyxis Oncology, Inc. Gpnmb antibodies and methods of use
JP2024520497A (ja) 2021-05-28 2024-05-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｃｍ－ｔｍａバイオマーカーを検出するための方法
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
CA3221281A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
MX2024001277A (es) 2021-07-26 2024-02-15 Abcuro Inc Anticuerpos agotadores del miembro 1 de la subfamilia g del receptor tipo lectina de celulas asesinas (klrg1).
EP4130028A1 (en) 2021-08-03 2023-02-08 Rhazes Therapeutics Ltd Engineered tcr complex and methods of using same
EP4380966A2 (en) 2021-08-03 2024-06-12 Genicity Limited Engineered tcr complex and methods of using same
US11879010B2 (en) 2021-09-30 2024-01-23 The Charlotte Mecklenburg Hospital Authority Methods and compositions for pretargeted immunotherapy
EP4413040A1 (en) 2021-10-06 2024-08-14 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
JP2024540017A (ja) 2021-10-29 2024-10-31 シージェン インコーポレイテッド 抗ｐｄ－１抗体と、抗ｃｄ３０抗体－薬物コンジュゲートとの組合せを用いてがんを処置する方法
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
EP4440594A2 (en) 2021-11-29 2024-10-09 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
AU2022411573A1 (en) 2021-12-17 2024-06-27 Shanghai Henlius Biologics Co., Ltd. Anti-ox40 antibodies and methods of use
EP4448578A1 (en) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
CA3245762A1 (en) 2022-03-25 2023-09-28 Shanghai Henlius Biologics Co Ltd ANTI-MSLN ANTIBODIES AND METHODS OF USE
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
JP2025513022A (ja) 2022-04-10 2025-04-22 イミュノミック セラピューティックス， インコーポレイテッド 免疫応答増強遺伝子を含むバイシストロニックｌａｍｐ構築物およびその使用方法
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
US20250302982A1 (en) 2022-05-06 2025-10-02 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
JP2025516590A (ja) 2022-05-12 2025-05-30 ビオンテック・ソシエタス・エウロパエア プログラム死－１タンパク質に対するモノクローナル抗体および医薬におけるその使用
CN119731207A (zh) 2022-08-23 2025-03-28 小野药品工业株式会社 双特异性抗体
JP2025529318A (ja) 2022-09-06 2025-09-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を有する患者における診断及び予後バイオマーカプロファイル
WO2024059183A1 (en) 2022-09-14 2024-03-21 President And Fellows Of Harvard College Methods and compositions for modulation of piezo1 in the treatment of cancer
CN120435319A (zh) 2022-11-03 2025-08-05 思进公司 抗-avb6抗体和抗体-药物缀合物及其在癌症治疗中的用途
WO2024105205A1 (en) 2022-11-17 2024-05-23 Bayer Aktiengesellschaft Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups
WO2024108053A1 (en) 2022-11-17 2024-05-23 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
CN120302979A (zh) 2022-12-01 2025-07-11 生物技术公司 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
WO2025038750A2 (en) 2023-08-14 2025-02-20 President And Fellows Of Harvard College Methods and compositions for treating cancer
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
TW202535938A (zh) 2023-10-17 2025-09-16 德商拜恩迪克公司 專一性結合ｃｄ３之抗原結合蛋白及其醫藥用途
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies
WO2025163468A1 (en) 2024-01-30 2025-08-07 Seagen Inc. Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
WO2025196639A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody-drug conjugates, and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
CA1142466A (en) * 1979-01-09 1983-03-08 Cesar Milstein Cell lines
US4363799A (en) * 1979-03-20 1982-12-14 Ortho Pharmaceutical Corporation Monoclonal antibody to human T cells, and methods for preparing same
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4361549A (en) * 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4284412A (en) * 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses
US4271145A (en) * 1979-10-22 1981-06-02 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4349528A (en) * 1979-11-21 1982-09-14 The Wistar Institute Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361647A (en) * 1980-05-22 1982-11-30 Palo Alto Medical Research Foundation Sandwich immunoassay and compositions for use therein
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4359457A (en) * 1980-09-30 1982-11-16 Neville Jr David M Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
US4356117A (en) * 1980-10-23 1982-10-26 U.S. Govt., Dept. Of Health & Human Services Chemical modifications of proteins which induce new receptor specificities and therefore elicit new effects in cells
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity

Also Published As

Publication number Publication date
JPS5859994A (ja) 1983-04-09
DE3276007D1 (en) 1987-05-14
EP0068763A2 (en) 1983-01-05
EP0068763A3 (en) 1983-06-08
JPH084496B2 (ja) 1996-01-24
US4474893A (en) 1984-10-02
ATE26464T1 (de) 1987-04-15
CA1190873A (en) 1985-07-23
JPH04228067A (ja) 1992-08-18
EP0068763B2 (en) 1993-04-21
JPH0565155B2 (en:Method) 1993-09-17
EP0068763B1 (en) 1987-04-08
JPH04228068A (ja) 1992-08-18

Similar Documents

Publication Publication Date Title
US4474893A (en) Recombinant monoclonal antibodies
US4714681A (en) Quadroma cells and trioma cells and methods for the production of same
US4935343A (en) Monoclonal antibodies for interleukin-1β
US4921790A (en) Tumor specific assay for CA125 ovarian cancer antigen
JP2837160B2 (ja) ヒト腫瘍壊死因子に対するモノクローナル抗体を含有する敗血症治療薬及びリューマチ性疾患治療薬
KR900003923B1 (ko) 인체 암종양과 관련된 항원에 대한 단일클론성 항체
JPH0753119B2 (ja) 二重特異性を有する抗体の製造方法
CA1339095C (en) Purification of cancer-associated protein and preparation of antibody thereto
JP7313659B2 (ja) 試料中のｈｍｇｂ１の測定方法及び測定試薬
JPS62174100A (ja) Ｇｔ―２に特異的なモノクローナル抗体
JP4663831B2 (ja) モノクローナル抗体、細胞株及びｎ１，ｎ１２−ジアセチルスペルミンの測定法
WO1986002359A1 (en) Monoclonal antibodies and their use
JP4664340B2 (ja) モノクローナル抗体、細胞株及びｎ１，ｎ１２−ジアセチルスペルミンの測定法
WO1986002355A1 (en) Monoclonal antibodies and their use
FI93469B (fi) Menetelmä hybridoomasolulinjan ja sen tuottaman vasta-aineen tuottamiseksi
JP3036545B2 (ja) モノクローナル抗体とこれを産生するハイブリドーマ細胞株、およびこれを用いる免疫学的測定法
WO1986002354A1 (en) Monoclonal antibodies and their use
WO1986002356A1 (en) Monoclonal antibodies and their use
JPH06504424A (ja) モノクローナル抗ＩｇＭ抗体、その生産と使用、およびそれらを生産するためのハイブリドーマ
JPS61126100A (ja) 抗ＴｄＴモノクロ−ナル抗体及びその製造法
JPH0458960B2 (en:Method)
JPH02131574A (ja) ミニクローン
JPH06209788A (ja) ヒト可溶性ｉｃａｍ−１の免疫学的測定法、その測定用抗 体および測定用キット
WO1988001386A1 (en) Production and diagnostic use of antibodies against pancreatic alpha-amylase
JPH06107695A (ja) 新規ヒト血液細胞関連抗原及びそれを認識する単クローン抗体